A 32-year-old woman with a severe opioid use disorder (primarily intravenous heroin) presents to an outpatient addiction clinic. She is highly motivated to achieve long-term abstinence and requests to start extended-release intramuscular naltrexone therapy, as her occupation makes daily medication adherence difficult. She used heroin this morning. Arrange the following clinical steps in the most appropriate chronological order for safely initiating extended-release naltrexone therapy in this patient.
- 1Complete a medically supervised opioid withdrawal.
- 2Maintain complete opioid abstinence for a minimum of 7 to 10 days.
- 3Obtain a urine drug screen to objectively confirm the absence of opioids.
- 4Perform a naloxone challenge test to assess for latent physical dependence.
- 5Administer the first dose of extended-release intramuscular naltrexone.
Answer
The correct chronological sequence is: complete medically supervised withdrawal, maintain 7 to 10 days of complete abstinence, obtain a confirmatory urine drug screen, perform a naloxone challenge test, and finally administer the extended-release naltrexone.
Naltrexone is a high-affinity competitive mu-opioid receptor antagonist used for relapse prevention in opioid use disorder. If administered to a patient who is physically dependent on opioids, it will abruptly displace the agonist, causing severe, rapid-onset precipitated withdrawal. Therefore, the standard of care requires complete opioid detoxification followed by a mandatory 7 to 10-day opioid-free period (up to 14 days for long-acting opioids like methadone). Objective evidence of abstinence is then obtained via urine drug screening. Because patient reporting and urine screens may not capture all synthetic opioids, a naloxone challenge (using a short-acting antagonist) is performed. If the challenge is negative (no withdrawal symptoms), the patient has no residual physiological dependence, and the long-acting intramuscular naltrexone can be safely administered.
Step-by-Step Solution
Key Concept
Initiation of extended-release naltrexone for opioid use disorder requires complete detoxification followed by a 7 to 10-day opioid-free period, confirmed by urine toxicology and a negative naloxone challenge test, to prevent severe precipitated withdrawal.